Proenkephalin Levels and Its Determinants in Patients with End-Stage Kidney Disease Treated with Hemodialysis and Peritoneal Dialysis
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241915015 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Wiktoria Grycuk und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, Heart Failure, Peritoneal Dialysis, Acute Kidney Injury. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Warsaw Medical University, Poland, Medical University of Warsaw, Poland.
Abstract (Originalsprache)
Recently, proenkephalin A (PENK A) has been shown to reflect glomerular dysfunction and to predict new-onset acute kidney injury and heart failure. While previous studies have investigated PENK A as a biomarker in individuals with preserved renal function, PENK A concentration in patients with end-stage kidney disease (ESKD) was not investigated. Plasma PENK A concentration was assessed in 88 patients with ESKD treated with hemodialysis (HD) or peritoneal dialysis (PD), and its associations with kidney function and heart failure indicators were investigated. In HD patients, the difference in PENK A levels before and after hemodialysis, was measured and further assessed for an association with the type of HD membrane used. PENK A levels did not differ significantly between HD and PD patients. In HD patients, the median PENK A concentration was significantly higher before than after hemodialysis (1.368 vs. 2.061, p = 0.003). No correlation was found between PENK A level and urea (p = 0.192), eGFR (p = 0.922), dialysis vintage (p = 0.637), and residual urine output (p = 0.784). Heart failure (p = 0.961), EF (p = 0.361), and NT-proBNP (p = 0.949) were not associated with increased PENK A concentration. PENK A does not reflect renal function and cardiac status in patients with ESKD. Further research is required to establish the clinical utility of the new biomarker in patients with impaired kidney function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.
ORCID-Profile: Wiktoria Grycuk, Zuzanna Jakubowska, Jolanta Małyszko
Förderung
- Warsaw Medical University, Poland
- Medical University of Warsaw, Poland
Zitieren
APA
Grycuk, W., Jakubowska, Z., & Małyszko, J. (2023). Proenkephalin Levels and Its Determinants in Patients with End-Stage Kidney Disease Treated with Hemodialysis and Peritoneal Dialysis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241915015
Vancouver
Grycuk W, Jakubowska Z, Małyszko J. Proenkephalin Levels and Its Determinants in Patients with End-Stage Kidney Disease Treated with Hemodialysis and Peritoneal Dialysis. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241915015
BibTeX
@article{Grycuk2023,
author = {Grycuk, Wiktoria and Jakubowska, Zuzanna and Małyszko, Jolanta},
title = {Proenkephalin Levels and Its Determinants in Patients with End-Stage Kidney Disease Treated with Hemodialysis and Peritoneal Dialysis},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241915015}
}
EUVIMED